公开(公告)号：US11000569B2

公开(公告)日：2021-05-11

申请号：US16073860

申请日：2017-01-20

Applicant: Shandong Zhonghai Pharmaceutical CO. LTD

Inventor： Qian Cheng ,  Baozhen Xu ,  Long Cheng

IPC: A61K38/16 ,  A61K31/715 ,  A61P1/16 ,  A61K31/7012 ,  A61K36/05 ,  A61K36/752 ,  A61K36/315 ,  A61K36/02 ,  A61K36/03 ,  A61K36/04 ,  A61K36/896 ,  A61K31/4025

Abstract: A medicament for use in treating fatty liver, hepatitis and cirrhosis, the medicament includes a marine algal glycoprotein.

公开(公告)号：US10925924B2

公开(公告)日：2021-02-23

申请号：US15126794

申请日：2015-03-17

Applicant: Apeptico Forschung UND Entwicklung GMBH

Inventor： Bernhard Fischer

IPC: A61K9/00 ,  A61K9/14 ,  A61K38/00 ,  A61K38/12 ,  A61K31/351 ,  A61K31/215 ,  A61K31/7012 ,  A61K45/06

Abstract: Disclosed is a dry-powder peptide medicament with a non-typical concentration of carbohydrate excipient, as well as said medicament for use in treatment or prevention of a disease or condition, as well as methods for manufacturing said medicament.

公开(公告)号：US20200046747A1

公开(公告)日：2020-02-13

申请号：US16655004

申请日：2019-10-16

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic

Inventor： Marjan Huizing ,  May C. Malicdan ,  Nuria Carrillo

IPC: A61K31/7008 ,  A61K47/20 ,  A61K9/50 ,  A61K9/127 ,  A61K9/00 ,  A61P9/00 ,  A61K45/06 ,  A61K31/7012 ,  A61K31/702 ,  A61K31/7088

Abstract: Methods are disclosed for treating a subject with a vascular or cardiac disorder associated with oxidative stress. Methods are disclosed for treating a subject with GNE myopathy that has impaired cardiac function. These methods include administering to the subject a therapeutically effective amount of a sialic acid precursor, sialic acid, or one or more sialylated compounds, mannosamine, N-acetyl mannosamine or a derivative thereof. In other embodiments, methods are disclosed for detecting a disorder associated with oxidative stress.

公开(公告)号：US20190388539A1

公开(公告)日：2019-12-26

申请号：US16535610

申请日：2019-08-08

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Daniel B. DIX ,  Kelly FRYE ,  Susan KAUTZ

IPC: A61K39/395 ,  A61K9/08 ,  A61K9/19 ,  A61K31/4172 ,  A61K31/7012 ,  A61K38/16 ,  A61K38/17 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  C07K14/71 ,  C07K16/22 ,  A61K9/00

Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.

公开(公告)号：US10406226B2

公开(公告)日：2019-09-10

申请号：US15692893

申请日：2017-08-31

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Daniel B. Dix ,  Kelly Frye ,  Susan Kautz

IPC: A61K39/395 ,  A61K9/00 ,  A61K38/17 ,  C07K14/71 ,  C07K16/22 ,  A61K9/08 ,  A61K9/19 ,  A61K31/4172 ,  A61K31/7012 ,  A61K47/02 ,  A61K47/26 ,  A61K47/10 ,  A61K47/18 ,  A61K47/22 ,  A61K47/12 ,  A61K38/16

Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.

公开(公告)号：US10350188B2

公开(公告)日：2019-07-16

申请号：US14370916

申请日：2011-11-04

Applicant: Paul Zachary Josefowitz ,  Constantin Melas-Kyriazl ,  Myron R. Szewczuk

Inventor： Paul Zachary Josefowitz ,  Myron R. Szewczuk

IPC: A61K31/215 ,  A61K31/505 ,  A61K31/135 ,  A61K31/70 ,  A61K31/00 ,  A61K33/24 ,  C07D309/30 ,  C07D317/46 ,  A61K45/06 ,  A61K31/138 ,  A61K31/337 ,  A61K31/357 ,  A61K31/513 ,  A61K31/519 ,  A61K31/7012 ,  A61K31/7068 ,  A61K31/196 ,  A61K31/351 ,  C07C233/23 ,  C07C233/41 ,  C07D317/68 ,  A61K9/00

Abstract: Use of Neu1 sialidase inhibitors for the treatment of cancer as a monotherapy or in combination with known chemotherapeutics. Preferably, Neu1 sialidase inhibitors are oseltamivir phosphate or 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (DANA) or analogs thereof.

公开(公告)号：US10342812B2

公开(公告)日：2019-07-09

申请号：US14803725

申请日：2015-07-20

Applicant: Huiru Wang

Inventor： Huiru Wang

IPC: A61K31/7012 ,  A61K31/198 ,  A61K31/70 ,  A61K31/7008 ,  A61K36/8962 ,  A61K39/00 ,  C40B60/12

Abstract: The present disclosure discloses simple and efficient glycan- or carbohydrate-based processes or methods for the rapid identification of biological markers and therapeutic targets especially glycan-related targets of infectious diseases, cancers, autoimmune diseases, allergies, inflammation, toxicity, obesity and/or other disorders of humans, animals, plants and other organisms. Therefore, novel methods and products for the diagnosis, prevention, and treatment of such diseases obtainable based on these therapeutic targets can be developed.

公开(公告)号：US10307466B2

公开(公告)日：2019-06-04

申请号：US15124432

申请日：2015-03-10

Applicant: SARAYA CO., LTD.

Inventor： Yasushi Suzuki ,  Hiromitsu Tabata ,  Mizuyuki Ryu ,  Nanase Ishii ,  Takashi Takeuchi ,  Yasuki Matsumura ,  Kentaro Matsumiya

IPC: A61K31/7012 ,  A61K38/40 ,  A61K45/06 ,  A23L33/115 ,  A23L9/10 ,  A23G1/36 ,  A61K9/00 ,  A61K9/107 ,  A61K47/06 ,  A61K47/26 ,  A61K47/44

Abstract: The present invention provides an orally administered composition comprising a sophorolipid, a physiologically active substance, and an oil or fat, wherein the physiologically active substance exhibits an improved bioavailability.

公开(公告)号：US20180256616A1

公开(公告)日：2018-09-13

申请号：US15748130

申请日：2016-07-28

Applicant: Sivanaray, Inc.

Inventor： Nallagounder Kuppusamy

IPC: A61K31/7004 ,  A61K31/7012 ,  A61P1/16 ,  A61P3/06

CPC classification number: A61K31/7004 ,  A61K9/141 ,  A61K9/2004 ,  A61K31/7012 ,  A61P1/16 ,  A61P3/00 ,  A61P3/06 ,  A61K2300/00

Abstract: The inventive subject matter provides compositions and methods for reducing serum levels of at least one biomarker associated with a lipid or liver-related condition. Preferred compositions include a set of actives that consists essentially of at least two saccharides selected from galacturonic acid, galactose, arabinose, rhamnose, glucose, xylose, and mannose.

公开(公告)号：US09956196B2

公开(公告)日：2018-05-01

申请号：US14585978

申请日：2014-12-30

Applicant: Shi-Lung Lin ,  Samantha Chang-Lin ,  Yi-Wen Lin ,  Donald Chang

Inventor： Shi-Lung Lin ,  Samantha Chang-Lin ,  Yi-Wen Lin ,  Donald Chang

IPC: A61K31/7012 ,  A61K31/221 ,  C12N15/11 ,  C12N15/113 ,  A61K9/00 ,  A61K9/08 ,  A61K31/7024

CPC classification number: A61K31/221 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/7012 ,  A61K31/7024 ,  C12N15/111 ,  C12N15/113 ,  C12N2310/141 ,  C12N2320/32 ,  C12N2330/50 ,  C12N2330/51

Abstract: This invention is related to a novel sugar-like chemical composition and its use for diabetes therapy. Particularly, the present invention teaches the use of monosaccharide-like glycylated sugar alcohol compounds to block or reduce sugar absorption in diabetes patients, so as to prevent the risk of hyperglycemia symptoms. Glycylation of sugar alcohols is a totally novel reaction that has never been reported before. Therefore, the novelty of the present invention is that for the first time glycylated sugar alcohols not only was found but also was found to be useful for treating Diabetes mellitus. In addition, the present invention teaches a method for producing these glycylated sugar alcohols. In sum, the present invention includes not only a kind of novel sugar-like chemical compositions and its use for treating diabetes but also a state-of-the-art protocol and methodology for producing such a novel composition via glycylation of sugars and sugar alcohols.